@article{TCR20235,
author = {Matteo Brighenti and Marcello Tiseo},
title = {Is there still room for anti-angiogenic agents in small cell lung cancer?},
journal = {Translational Cancer Research},
volume = {7},
number = {Suppl 4},
year = {2018},
keywords = {},
abstract = {We thank the authors of the editorials (1-4) in Transl Cancer Res for their comments on the GOIRC-AIFA FARM6PMFJM trial (5). This is the first randomized prospective phase III study assessing the role of adding bevacizumab to standard platinum-etoposide chemotherapy on survival outcome in the first-line treatment of extensive stage (ES) small cell lung cancer (SCLC).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/20235}
}